levofloxacin

Phase 3

Johnson & Johnson (JNJ)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

2 competitors in Pneumonia

View Full Landscape

Drug Information

Target Indication

Pneumonia

Clinical Trial

NCT00236821

Last updated: 12/4/2025

Patent & Exclusivity

No Patent DataRLD

Application

NDA 020634

Source: FDA Orange Book

Regulatory Approvals

EMA3/25/2015

Quinsair

Quinsair is indicated for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis. Consideration should be given to official guidance on the appropriate use of antibacterial agents.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

JNJ

Johnson & Johnson

Pharmaceutical Preparations•North America•NYSE

Related Pipeline

galantamine ERPhase 3

Alzheimer's Disease

Test acetaminophenPhase 3

Post-operative Dental Pain

CG 5503;tapentadolPhase 3

Osteoarthritis

tapentadol (CG5503) ERPhase 3

Low Back Pain

RivaroxabanPhase 3

Atrial Fibrillation

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts